Literature DB >> 30181038

Validation of a High-End Virtual Reality Simulator for Training Transurethral Resection of Bladder Tumors.

Gerald B Schulz1, Tobias Grimm2, Alexander Buchner2, Friedrich Jokisch2, Jozefina Casuscelli2, Alexander Kretschmer2, Jan-Niclas Mumm2, Brigitte Ziegelmüller2, Christian G Stief2, Alexander Karl2.   

Abstract

OBJECTIVE: The oncological outcome in patients with bladder cancer (BC) significantly correlates with the quality of transurethral resection of bladder tumors (TUR-BT). Virtual reality (VR) training simulators have been developed to improve surgical skills. We evaluated the advantages and limitations of the novel Uro Trainer (UT) (Karl Storz GmbH, Germany) with respect to training for TUR-BT.
DESIGN: Participants underwent VR training based on 4 different TUR-BT cases accompanied by self-assessment and evaluation questionnaires. Results were compared between experienced endourologists and novices, and furthermore, correlated with self-rated capabilities for content and construct validity. Student's t tests, Pearson's correlation, and chi-squared tests were performed for statistical evaluation.
SETTING: The study was performed at the tertiary care urological department of the Ludwig-Maximilians-University, Munich, Germany. PARTICIPANTS: A total of 22 urological physicians, including residents and consultants, were included in the study.
RESULTS: There is a need to improve TUR-BT training as 27.3% of the participants had already experienced overtaxing situations during TUR-BT and only a few reported of high satisfaction with the classical "see one-do one" teaching mode. Construct validity was demonstrated, as consultants achieved significantly higher overall scores (p < 0.001) and safety (p = 0.004) and visualization (p = 0.001) subscores. Interestingly, the self-assessed capability to perform a TUR-BT correlated significantly (p = 0.01) with overall UT scores. Significant progress of self-rated abilities was shown for several parameters, including inspection (p = 0.046) and resection (p = 0.026). Although participants indicated improvements in several procedural skills and overall benefit of the VR training with the UT was rated 4.6 on a 5-point scale by consultants, limitations of the UT were demonstrated predominantly for tissue feedback and authenticity of different tissue layers.
CONCLUSIONS: The novel VR simulator showed a high face and construct validity, and therefore has a great potential to complement endourological training.
Copyright © 2018 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medical Knowledge; Practice-Based Learning and Improvement; Self-assessment; Simulation training; Urinary bladder neoplasms; Urologic surgical procedures; Virtual reality

Year:  2018        PMID: 30181038     DOI: 10.1016/j.jsurg.2018.08.001

Source DB:  PubMed          Journal:  J Surg Educ        ISSN: 1878-7452            Impact factor:   2.891


  4 in total

1.  SlicerVR for Medical Intervention Training and Planning in Immersive Virtual Reality.

Authors:  Csaba Pinter; Andras Lasso; Saleh Choueib; Mark Asselin; Jean-Christophe Fillion-Robin; Jean-Baptiste Vimort; Ken Martin; Matthew A Jolley; Gabor Fichtinger
Journal:  IEEE Trans Med Robot Bionics       Date:  2020-03-26

2.  Teaching with Disruptive Technology: The Use of Augmented, Virtual, and Mixed Reality (HoloLens) for Disease Education.

Authors:  Zane Stromberga; Charlotte Phelps; Jessica Smith; Christian Moro
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Review of the effect of 3D medical printing and virtual reality on urology training with ‘MedTRain3DModsim’ Erasmus + European Union Project

Authors:  İlkan Tatar; Emre Huri; İlker Selçuk; Young Lee Moon; Alberto Paoluzzi; Andreas Skolarikos
Journal:  Turk J Med Sci       Date:  2019-10-24       Impact factor: 0.973

Review 4.  [Virtual and augmented reality in urology].

Authors:  P Sparwasser; M Haack; L Frey; A Haferkamp; H Borgmann
Journal:  Urologe A       Date:  2021-12-22       Impact factor: 0.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.